Related Experiment Video
Updated: Aug 15, 2025
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Investigating the Role of DUSP4 in Uveal Melanoma
Karen Aughton1, Dorota Sabat-Pospiech1, Samantha Barlow1,2
1Liverpool Ocular Oncology Research Group, University of Liverpool, Molecular and Clinical Cancer Medicine, Institute of Systems Molecular & Integrative Biology, University of Liverpool, Liverpool, UK.
Purpose:
Dual-specificity phosphatase 4 (DUSP4) inactivates factors in the mitogen-activated protein kinase (MAPK) signaling cascade, activated in uveal melanoma (UM) by mutations in upstream G-protein α subunits GNAQ/11 in >90% cases. This study examined whether DUSP4 (1) protein expression in primary UM (pUM) was a biomarker of metastatic risk and (2) knockdown sensitized UM cells to therapeutic agents, selumetinib or doxorubicin.
Methods:
DUSP4 mRNA data from The Cancer Genome Atlas and DUSP4 protein expression examined using immunohistochemistry in 28 cases of pUM were evaluated for association with clinical, genetic, and histological features. In vitro cytotoxic drug assays tested the efficacy of selumetinib and doxorubicin in UM cell lines with/without small interfering RNA DUSP4 gene silencing.
Results:
DUSP4 protein expression was observed in 93% of cases, with strong nuclear positivity in 79%. Despite higher DUSP4 messenger RNA levels in disomy 3/wild-type BAP1 UM, there was no significant association of nDUSP4 protein with these metastatic risk predictors or outcome. DUSP4 expression in UM cell lines varied. DUSP4 silencing in Mel202, MP46, and MP41 cells did not affect ERK1/2 or phospho-ERK levels. Despite increased phospho-ERK levels in Mel285, no cell line showed enhanced sensitivity to selumetinib/doxorubicin.
Conclusions:
DUSP4 protein expression is not a biomarker of UM metastatic risk. DUSP4 plays a complex role in oncogenesis, as reported in other cancers, and further work is required to fully understand its functional role in the MAPK pathway.
Translational Relevance:
Understanding the role of phosphatases, such as DUSP4, in the control of intracellular signaling cascades will facilitate our ability to identify successful treatment options.
Insights
Dual-specificity phosphatase 4 (DUSP4) protein expression does not predict metastatic risk in uveal melanoma (UM). Silencing DUSP4 did not increase UM cell sensitivity to targeted therapies like selumetinib or doxorubicin.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling
Background:
- Uveal melanoma (UM) frequently harbors GNAQ/11 mutations activating the MAPK pathway.
- Dual-specificity phosphatase 4 (DUSP4) is a negative regulator of MAPK signaling.
- The role of DUSP4 in UM pathogenesis and treatment response remains unclear.
Purpose of the Study:
- To investigate DUSP4 protein expression as a biomarker for metastatic risk in primary UM (pUM).
- To determine if DUSP4 knockdown sensitizes UM cells to selumetinib or doxorubicin therapy.
Main Methods:
- DUSP4 mRNA and protein levels were analyzed in pUM samples (n=28) and correlated with clinical/genetic features.
- Immunohistochemistry assessed DUSP4 protein expression.
- In vitro drug assays evaluated UM cell sensitivity to selumetinib and doxorubicin following DUSP4 gene silencing via siRNA.
Main Results:
- DUSP4 protein was expressed in 93% of pUM cases, with strong nuclear localization in 79%.
- No significant association was found between DUSP4 protein levels and metastatic risk predictors (e.g., disomy 3, BAP1 status) or patient outcome.
- DUSP4 silencing did not alter ERK1/2 phosphorylation or enhance sensitivity to selumetinib/doxorubicin in UM cell lines.
Conclusions:
- DUSP4 protein expression is not a reliable biomarker for predicting metastatic risk in uveal melanoma.
- DUSP4's role in UM oncogenesis and MAPK pathway regulation requires further investigation.
- Targeting DUSP4 may not be a viable strategy to enhance current UM therapies.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:35Cancer Cell Migration through Invadopodia
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...